--- title: "A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Momentum And Analyst Discount" type: "News" locale: "en" url: "https://longbridge.com/en/news/284160262.md" description: "InnoCare Pharma (SEHK:9969) has seen a 4.4% share price increase recently, with a mixed performance over the past week, month, and three months. The stock is up 17.6% year-to-date and has a one-year total return of 44.97%. Analysts suggest a fair value of HK$21.27, indicating it is undervalued at the current price of HK$14.70, with a significant intrinsic value gap of 59%. However, there is disagreement among analysts regarding future price targets, ranging from HK$8.2 to HK$25.79, reflecting varying expectations of growth and profitability." datetime: "2026-04-27T06:07:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284160262.md) - [en](https://longbridge.com/en/news/284160262.md) - [zh-HK](https://longbridge.com/zh-HK/news/284160262.md) --- # A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Momentum And Analyst Discount ## What recent performance says about InnoCare Pharma InnoCare Pharma (SEHK:9969) has caught investor attention after a 4.4% move in the latest session, alongside a mixed pattern over the past week, month and past 3 months that highlights shifting sentiment toward the stock. Over the past week the share price shows a 6.5% decline, while the past month return sits at 12.1% and the past 3 months at 26.4%. Year to date the stock is up 17.6%, with a 1 year total return of 44.97% and a 3 year total return of 63.33%. Over 5 years, the total return is a 40.24% decline. See our latest analysis for InnoCare Pharma. The HK$14.7 share price move, with a 4.4% 1 day share price return and a 26.4% 90 day share price return against a weaker recent 7 day patch, points to momentum that has been building over the medium term despite earlier long term volatility shown in the 5 year total shareholder return. If you are weighing InnoCare Pharma's recent swing, it can be helpful to compare it with other healthcare names by scanning 127 healthcare AI stocks With InnoCare Pharma trading at HK$14.70 against an indicated intrinsic value gap of about 59% and a sizeable discount to analyst targets, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth? ## Most Popular Narrative: 30.9% Undervalued At HK$14.70, the most followed narrative places InnoCare Pharma's fair value at HK$21.27, which points to a sizeable valuation gap built on specific growth and profitability assumptions. > _The analysts have a consensus price target of HK$15.606 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$25.79, and the most bearish reporting a price target of just HK$8.2._ _Read the complete narrative._ Curious what justifies a fair value meaningfully above HK$14.70? The narrative rests on assumptions of aggressive revenue expansion, a sharp swing in profitability and a future earnings multiple often associated with high growth stories. **Result: Fair Value of HK$21.27 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on high biotech R&D spend paying off and key drugs gaining traction, while competition and pipeline setbacks could quickly weaken that bullish setup. Find out about the key risks to this InnoCare Pharma narrative. ## Next Steps With mixed signals across valuation, risks and rewards, what does the balance look like to you, and how quickly do you want to form a view based on the underlying data? To stress test your thinking against both the upside and the concerns flagged by the market, start by checking the 4 key rewards and 2 important warning signs ## Looking for more investment ideas? If you stop with just one company, you might miss opportunities right in front of you. Use the Simply Wall St Screener to quickly surface fresh ideas tailored to your style. - Spot potential mispriced opportunities early by scanning 230 high quality undervalued stocks that combine quality fundamentals with room for a re rating. - Strengthen your focus on resilience by checking 310 resilient stocks with low risk scores that score well on stability and balance sheet strength. - Get ahead of the crowd by reviewing the screener containing 564 high quality undiscovered gems before they end up on everyone else's radar. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [09969.HK](https://longbridge.com/en/quote/09969.HK.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [688428.CN](https://longbridge.com/en/quote/688428.CN.md) ## Related News & Research - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver](https://longbridge.com/en/news/284017056.md)